Table 1. Chemotherapies and targeted therapies inducing breast cancer dormancy or enabling dormancy escape in in vitro models.
Bcl-2, B-cell lymphoma 2 regulator protein; Oct-4, octamer-binding transcription factor 4; Sox-2 SRY-box transcription factor 2; G-CSF, granulocyte colony-stimulating factor; Tie2, tyrosine kinase 2 with immunoglobulin-like and epidermal growth factor homology domains.
| Drug name | Type of therapy | Platform used | Mechanism involved | Effect on dormancy | Reference |
|---|---|---|---|---|---|
| Docetaxel | Chemotherapy | SUM159 cells (TNBC) on 2D TCPS | – | Induction | (189) |
| Doxorubicin | Chemotherapy | SUM159 cells (TNBC) on 2D TCPS | – | Induction | (189) |
| Paclitaxel | Chemotherapy | MDA-MB-231-Br spheroids on 2D TCPS | Low ERK/p38 activity ratio | Induction | (190) |
| Carboplatin | Chemotherapy | MDA-MB-231 on 2D TCPS and 3D polycaprolactone scaffolds | Increase in cyclin D1, increase in Bcl-2, Oct-4, and Sox-2 | Induction | (191) |
| Docetaxel | Chemotherapy | D2.0R in 3D Matrigel with murine endothelial cells and embryonic fibroblasts | Release of IL-6 and G-CSF | Escape | (35) |
| Tamoxifen | Targeted therapy | MCF7 on 2D TCPS | OXPHOS down-regulation | Induction | (49) |
| Fulvestrant | Targeted therapy | MCF7 on 2D TCPS | OXPHOS down-regulation | Induction | (49) |
| 4-Hydroxytamoxifen | Targeted therapy | MCF7 in bone marrow endothelial niche on 3D Matrigel | Endothelial Tie2 receptor expression and integrin β1 expression | Escape | (38) |